Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C.

While the overall steatosis grade showed an increasing trend, changes occurred in both directions, with 7.8% of the study population developing mild hepatic steatosis, 23.7% experiencing aggravation, 62.1% showing no change, and 14.2% achieving improvement ( Table 2 ).

also in 63,971 other papers